Monday, December 4, 2023
Statins represent the cornerstone of treating dyslipidemia, which is associated with an increased risk for cardiovascular disease. However, statin selection can be challenging in patients at high risk for cardiovascular disease or in special patient populations. This educational curriculum will focus on educating healthcare providers practicing in numerous specialties, and on the considerations needed when choosing a statin for certain patient populations, including patients with diabetes or prediabetes, the elderly, and those living with HIV.
Chair
Clinical Associate Professor
Loyola Stritch School of Medicine
Director, Division of Cardiology Advocate Lutheran General Hospital
Past-President, National Lipid Association
Chicago, Illinois
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Akcea; Amgen; Novartis
Served as a speaker or a member of a speakers bureau for: Amarin; Amgen
Received grants for clinical research from: Amgen
Medical Director/President
Louisville Metabolic & Atherosclerosis Research Center
Louisville, Kentucky
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: 89Bio; Amarin; Esperion; Gelesis; Matinas;
Served as a speaker or a member of a speakers bureau for: Esperion; Novo Nordisk
Received grants for clinical research from: 89Bio; Acasti; Akcea; Allergan; Alon Medtech/Epitomee; Amarin; Amgen; AstraZeneca;
Axsome; BioHaven; Bionime; Boehringer Ingelheim; Civi; Eli Lilly; Esperion; Evidera; Gan and Lee; Home Access; Janssen; Johnson
and Johnson; Lexicon; Matinas; Merck; Metavant; Novartis; Novo Nordisk; Pfizer; Regeneron; Sanofi; Selecta; TIMI; Urovant
Chief Scientist, Midwest Biomedical Research
Chicago, Illinois
Adjunct Professor & Dean's Eminent Scholar
Department of Applied Health Science
Indiana University School of Public Health
Bloomington, Indiana
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: 89Bio; Acasti; Matinas BioPharma; Indiana University Faculty; National Dairy Council;
National Lipid Association; New Amsterdam Pharma; Novo Nordisk; Pharmavite
Received grants for clinical research from: Beef Checkoff; General Mills; Haas Avocado Board; Indiana University; Kellogg’s;
Matinas BioPharma; National Dairy Council; Pharmavite
President, European Atherosclerosis Society
Professor of Public Health and Honorary Consultant Cardiologist
Director of Imperial Centre for Cardiovascular Disease Prevention
Deputy Director of the Imperial Clinical Trials Unit, Head of Commercial Trials
Imperial College London
NIHR ARC National CV Lead
Chief Clinical Officer and Trials Lead
DISCOVER NOW- HDR UK Digital Innovation Hub
London, United Kingdom
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Kowa; Novartis; Novo Nordisk;
Pfizer
Served as a speaker or a member of a speakers bureau for: Amgen; Astra Zeneca; Boehringer Ingelheim; Daiichi Sankyo; Novartis;
Novo Nordisk; Pfizer; Sanofi
Received grants for clinical research from: Amgen; Daiichi Sankyo; Regeneron
Owns stock, stock options, or bonds from: Pemi31 Therapeutics
Certified and Registered Nurse Practitioner
University of Pennsylvania
West Chester, Pennsylvania
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Kaneka America; LDL Apheresis
Served as a speaker or a member of a speakers bureau for: Amarin; Amgen; Esperion; Speakers Bureau
Professor
Department of Clinical Pharmacy and Family Medicine
University of Colorado School of Pharmacy
President of the National Lipid Association
Aurora, Colorado
Has disclosed the following relevant financial relationships:
No relevant financial relationships.
The educational activities presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.
The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Medscape Education© Medscape, LLC
A panel of lipid experts discuss new guidelines and data, as well as simpler strategies for managing patients with complex
metabolic disease.
Drs Brown, Braun, and Saseen review major advancements in the 2018 cholesterol guidelines and provide guidance on how to tailor
therapy.
Dr Lynne Braun and Elizabeth Jackson discuss their step-wise approach to statin therapy in a patient with cardiometabolic
disease and NODM.
Drs Harold Bays and Laurie Braun discuss the differences in statins and their effect on hepatic fat and insulin sensitivity.
Clinical experts discuss applying the new lipid guidelines in patients at increased risk of new-onset diabetes with statin
therapy and CVD.
Drs Bays and Grinspoon discuss factors for statin-related metabolic abnormalities and strategies to reduce effects on insulin
sensitivity.
Join Drs Ray and Toth as they discuss the decision process in choosing different statin therapies in patients at risk for
T2D.
Dr Harold Bays leads an expert panel through an in depth discussion on statin therapy in patients with obesity to minimize
the effect on BG.
Drs Ray and Ginsberg discuss strategies for modifying statin therapy in patients at high risk for diabetes and progression
of CVD.
Statins and lipid management in geriatric patients: what do you need to consider?
Join Drs Harold Bays and Karen Aspry for an important discussion on the unique dyslipidemia needs of patients living with
HIV.
Dr Ray leads a brief discussion on how to address muscle symptoms and statin intolerance in different patient populations.
Drs Grinspoon and Underberg discuss strategies for optimal lipid management for patients living with HIV and dyslipidemia.
Drs Underberg and Saseen have an important, practical discussion about the screening and management of patients with statin
intolerance.
Join Drs Ray and Tokgözoğlu as they navigate the personalized needs of the elderly with respect to statin therapy.
A discussion of cardiovascular risk, dyslipidemia, and statin therapy in the HIV population.
Drs Underberg and Brown sit down to discuss strategies and options for managing high-risk patients with dyslipidemia.